Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology
- 15 March 2009
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (6) , 1891-1897
- https://doi.org/10.1158/1078-0432.ccr-08-2030
Abstract
In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.Keywords
This publication has 26 references indexed in Scilit:
- Novel Designs and End Points for Phase II Clinical TrialsClinical Cancer Research, 2009
- Effective Incorporation of Biomarkers into Phase II TrialsClinical Cancer Research, 2009
- Optimising the design of phase II oncology trials: The importance of randomisationEuropean Journal Of Cancer, 2008
- Processes for Quality Improvements in Radiation Oncology Clinical TrialsInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and LimitationsRadioGraphics, 2008
- CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal TumorAmerican Journal of Roentgenology, 2007
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal Of Cancer, 1999